Eilean Therapeutics c-MET inhibitor

Eilean Therapeutics' c-MET inhibitor is a small molecule designed to target the c-MET (Hepatocyte Growth Factor Receptor) tyrosine kinase. It is being developed for the treatment of solid tumors, with a particular focus on therapy-resistant lung cancer. The drug is part of Eilean's strategy to develop best-in-class and first-in-class inhibitors that target escape mutations in oncology. By modulating or inhibiting the c-MET receptor, the compound aims to disrupt signaling pathways that drive tumor growth and survival in patients who have developed resistance to other targeted therapies. As of early 2024, the program is in the discovery or preclinical stages of development.

Other names

c-MET inhibitorc-MET small molecule inhibitor